drugset / Trial / NCT07618325
A Study to Evaluate the Immune Response Features Following Vaccination With a Recombinant Respiratory Syncytial Virus Vaccine (CHO Cells)
Not yet recruiting
60 enrolled
MAXVAX Biotechnology Limited Liability Company
Henan Center for Disease Control and Prevention · collab
NaSingle-groupOpen-labelPrevention
Summary
The purpose of this study is to elucidate the molecular mechanism by which novel adjuvants enhance the immunogenicity of Respiratory Syncytial Virus (RSV) vaccines by regulating antigen-specific B cell affinity maturation and T cell memory formation.
Timeline
- Start
- 2026-06-02
- Primary completion
- 2028-06-30
- Completion
- 2028-08-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Recombinant Respiratory Syncytial Virus Vaccine (CHO Cell) | Vaccine | 0.5 ml | Intramuscular |